Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Actavis Group Stories

2013-10-03 23:21:24

Reportbuyer.com just published a new market research report: The World Generic Market Report 2013. London (PRWEB) October 03, 2013 A complete global analysis of the prospects for markets and companies in this dynamic industry sector Features and benefits of this thoroughly-researched and highly-regarded management report: High quality research and forecasts: Independent research, combined with detailed 5-year forecasts, informed commentary and unrivalled primary source data will aid your...

2013-02-19 08:32:01

PARSIPPANY, N.J., Feb. 19, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 13 percent to $1.75 billion for the fourth quarter 2012, compared to $1.54 billion in the fourth quarter 2011. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2012 was $1.59, compared to $1.77 per diluted share in the fourth quarter 2011, a decline of 10%. GAAP earnings per diluted share for the fourth quarter 2012 were $0.21, compared to $0.75 in the prior...

2012-10-31 19:21:47

PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the Global Generics management team, following the announcement of the completion of the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. "Since the announcement of our intention to acquire Actavis in April 2012, we have been...

2012-10-31 19:21:40

PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded the transaction through a combination of $1.8 billion in term loan borrowings and the issuance of $3.9 billion in senior unsecured...

2012-07-26 02:28:35

PARSIPPANY, N.J., July 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net income for the second quarter 2012 increased 42 percent to $181.4 million or $1.42 per diluted share on a non-GAAP basis, compared to $127.9 million or $1.01 per diluted share in the second quarter 2011. Net revenue increased 25 percent to $1.36 billion, compared to $1.08 billion in the second quarter 2011. On a GAAP basis, the Company recorded a loss of $62.2 million or $0.49 per...

2012-07-12 02:28:06

PARSIPPANY, N.J., July 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of Actavis Group. The information request was issued under notification requirements of the Hart.Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effect of...

2012-07-05 06:23:10

MORRISTOWN, N.J., July 5, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, announced that on June 29, 2012 it received tentative approval from the US Food and Drug Administration for Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg and 4mg, a generic equivalent to Shire's Intuniv(®). Based upon available information, Actavis believes that it is the first applicant to file an ANDA for Intuniv(®) containing a Paragraph IV certification,...

2012-06-25 02:26:15

MORRISTOWN, N.J., June 25, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII, (hereafter referred to as Mixed Amphetamine Salts ER Capsules), in all available strengths: 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg....

2012-05-30 02:26:20

MORRISTOWN, N.J., May 30, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Nifedipine Extended-Release Tablets, USP, 90mg, a generic equivalent to Bayer's Adalat® CC. Distribution of the product has commenced. Nifedipine Extended-Release Tablets, USP, 90mg has sales of approximately $23 million for the 12 months ending December 31, 2011, according to IMS Health. Commenting on the new...

2012-05-18 02:24:48

MORRISTOWN, N.J., May 18, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip® XL. Actavis believes this is the first generic Requip® XL available in the US. Distribution of the product has commenced. Requip® XL, 2mg, 4mg, 6mg, 8mg and 12mg, had US sales of approximately $59.4...